Unknown

Dataset Information

0

Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles.


ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causal agent of COVID-19 and stands at the center of the current global human pandemic, with death toll exceeding one million. The urgent need for a vaccine has led to the development of various immunization approaches. mRNA vaccines represent a cell-free, simple, and rapid platform for immunization, and therefore have been employed in recent studies toward the development of a SARS-CoV-2 vaccine. Herein, we present the design of an mRNA vaccine, based on lipid nanoparticles (LNPs)-encapsulated SARS-CoV-2 human Fc-conjugated receptor-binding domain (RBD-hFc). Several ionizable lipids have been evaluated in vivo in a luciferase (luc) mRNA reporter assay, and two leading LNPs formulations have been chosen for the subsequent RBD-hFc mRNA vaccine strategy. Intramuscular administration of LNP RBD-hFc mRNA elicited robust humoral response, a high level of neutralizing antibodies and a Th1-biased cellular response in BALB/c mice. The data in the current study demonstrate the potential of these lipids as promising candidates for LNP-based mRNA vaccines in general and for a COVID19 vaccine in particular.

SUBMITTER: Elia U 

PROVIDER: S-EPMC7860138 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered <i>via</i> Lipid Nanoparticles.

Elia Uri U   Ramishetti Srinivas S   Rosenfeld Ronit R   Dammes Niels N   Bar-Haim Erez E   Naidu Gonna Somu GS   Makdasi Efi E   Yahalom-Ronen Yfat Y   Tamir Hadas H   Paran Nir N   Cohen Ofer O   Peer Dan D  

ACS nano 20210122 6


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causal agent of COVID-19 and stands at the center of the current global human pandemic, with death toll exceeding one million. The urgent need for a vaccine has led to the development of various immunization approaches. mRNA vaccines represent a cell-free, simple, and rapid platform for immunization, and therefore have been employed in recent studies toward the development of a SARS-CoV-2 vaccine. Herein, we  ...[more]

Similar Datasets

| S-EPMC9349794 | biostudies-literature
| S-EPMC5899464 | biostudies-literature
| S-EPMC9508692 | biostudies-literature
| S-EPMC4624045 | biostudies-literature
| S-EPMC7692784 | biostudies-literature
| S-EPMC5267554 | biostudies-literature
| S-EPMC7581537 | biostudies-literature
| S-EPMC10076570 | biostudies-literature
| S-EPMC8353930 | biostudies-literature
| S-EPMC10652142 | biostudies-literature